Sutent Approved for GIST
|Posted by Julie Royster (jroyster) on Apr 23 2006|
|GIST In the News >>|
The Food and Drug Administration (FDA) on 1/26/2006 announced approval of Sutent (sunitinib), a new targeted anti-cancer treatment for patients with gastrointestinal stromal tumors (GIST), a rare stomach cancer, and advanced kidney cancer. Today's action marks the first time the agency has approved a new oncology product for two indications simultaneously.
Sutent, which received a priority review and was approved in less than six months, is a tyrosine kinase inhibitor working through multiple targets to deprive the tumor cells of the blood and nutrients needed to grow.
Full text at FDA site.
Last changed: Apr 23 2006 at 3:04 PMBack